Together, these data clearly portray the clinical benefit of SA-EA, PT-EA, and HT-EA fractions in the regulation of radiotherapy-orchestrated cellular localization of PC progression, driving survivin, ATG3, ATG5, ATG12, LC3A, LC3B, and beclin in residual PC tumors. The gene discussed is ATG12; the disease is pachyonychia congenita.